![Michael Garrett](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mr. Michael C.
Garrett is a Chief Executive Officer & Director at Exevir Bio BV.
He is on the Board of Directors at Exevir Bio BV.
Mr. Garrett was previously employed as a Vice President-Corporate & Strategic Development by SCYNEXIS, Inc. and a Co-Founder by Flamingo Therapeutics BV.
He received his undergraduate degree from The University of Southampton.
| Bedrijven | Functie | Begin |
|---|---|---|
Exevir Bio BV
 Exevir Bio BV Pharmaceuticals: MajorHealth Technology Develops antibody-based therapies | Algemeen Directeur | 01-12-2024 |
| Bedrijven | Functie | Einde |
|---|---|---|
Flamingo Therapeutics BV
 Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Provides RNA therapeutic drug development services | Oprichter | - |
| SCYNEXIS, INC. | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 4 |
|---|---|
SCYNEXIS, Inc.
 SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
The University of Southampton
 The University of Southampton Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Exevir Bio BV
Exevir Bio BV Pharmaceuticals: MajorHealth Technology Develops antibody-based therapies | Health Technology |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Provides RNA therapeutic drug development services | Commercial Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau
Kies MarketScreener 
